Cervical cancer: a tale from HPV infection to PARP inhibitors

Globally, cervical cancer (CxCa) ranks 4th common cancer among females and led to 569,847 incidences and 311,365 deaths in 2018. 80% of CxCa cases occur due to persistent infection with a high-risk subtype of human papillomavirus (HPV-16 and 18). Smoking, high parity, and co-infection with type 2 he...

Descripción completa

Detalles Bibliográficos
Autores principales: Mann, Minakshi, Singh, Vikram Pratap, Kumar, Lalit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311104/
https://www.ncbi.nlm.nih.gov/pubmed/37397551
http://dx.doi.org/10.1016/j.gendis.2022.09.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311104/
https://www.ncbi.nlm.nih.gov/pubmed/37397551
http://dx.doi.org/10.1016/j.gendis.2022.09.014

Ejemplares similares